Advertisement Pharmaceutical Business review - Page 12 of 5256 -
Pharmaceutical Business review is using cookies

ContinueLearn More
Close
January 12, 2026

MediLink and Roche announce exclusive licensing agreement for YL201c

MediLink Therapeutics has signed an exclusive licensing agreement with Roche for the development and commercialisation of YL201, an investigational antibody-drug conjugate (ADC) targeting B7H3 in various solid tumour types.

Continue
YL201 is an ADC that targets B7H3 and has been developed with MediLink’s proprietary TMALIN platform. Credit: Alpha Tauri 3D Graphics / Shutterstock.com.
January 12, 2026

Novartis to build fourth US radioligand therapy facility in Florida

Novartis currently has two radioligand therapies approved by the FDA and is developing additional candidates. Credit: Taljat David / Shutterstock.com.
January 9, 2026

Takeda and Halozyme sign global agreement for Enhanze technology

Enhanze technology uses recombinant human hyaluronidase PH20 and has reached one million patients with ten products worldwide. Credit: Elza_R / Shutterstock.com.

Contracts

January 23, 2025

Kamada to supply immune globulin products in Latin America

KAMRAB must be administered alongside a complete rabies vaccine regimen. Credit: Nappy on Unsplash.

Bavarian Nordic secures $156.8m US vaccine deal

Boehringer Ingelheim receives EC conditional marketing approval for spesolimab

Marinus Pharmaceuticals signs collaboration agreement with Tenacia Biotechnology

Deals

Deals January 20, 2025

Fermion and Simcere to partner on development of pain treatment drug

Pharmaceutical Business Review

WuXi Biologics and Sino Biopharm collaborate on monoclonal antibody discovery

Merck enhances ophthalmology portfolio with EyeBio acquisition

Biocon signs licensing and supply deal for diabetes drug in Brazil

Popular

  1. Santhera grants Agamree rights to Nxera for DMD
  2. Octapharma receives FDA approval for new Fibryga formulation in AFD
  3. Day One concludes Mersana Therapeutics acquisition
  4. Cellenkos gains FDA orphan drug status for CK0804 to treat myelofibrosis
  5. Zai Lab’s Augtyro receives NMPA approval for solid tumours in China

PRESS RELEASES

SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma and SHL Medical Enhance Home-Based Large-Volume Injections for Patients
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
SCHOTT Pharma Launches Ready-to-Use Polymer Cartridge
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Accelerating Self-Administration and Homecare: SCHOTT Pharma Launches Large-Volume Prefillable Glass Syringe
Pharmaceutical Business Review
Christian Mias to Succeed Andreas Reisse as CEO of SCHOTT Pharma
Pharmaceutical Business Review
LTS completes acquisition of Renaissance Lakewood, expanding global CDMO capabilities

Suppliers

Whitepapers

Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Smoothly Through the Production Process: EVERIC™ Strong/Smooth Test
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Strengths and Weaknesses of Different Prefilled Syringes for Injections in Hospitals: A Case Study by Niklas Niederwieser and Patrick Gallagher SCHOTT AG
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography
Tracking the Cracking: How to Optimise Pharma Fill-and-Finish Processes by Use of Strength Testing and Fractography